-+ 0.00%
-+ 0.00%
-+ 0.00%

Genmab Presented Pivotal Phase 3 Data From EPCORE FL-1 Trial Demonstrating Treatment With Fixed Duration EPKINLY Plus Rituximab And Lenalidomide Resulted In Statistically Significant And Clinically Meaningful Reduction In The Risk Of Disease Progression Or Death And Overall Response Vs R2 Alone

Benzinga·12/07/2025 22:34:07
Listen to the news

Genmab A/S (NASDAQ:GMAB) today announced primary data from the pivotal Phase 3 EPCORE® FL-1 study evaluating fixed duration EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide (EPKINLY + R2) in adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The study showed that treatment with EPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21, 95% CI: 0.14-0.31, p<0.0001) compared to standard of care R2. Additionally, the overall response rate (ORR) in patients treated with EPKINLY + R2 was 95% (95% CI: 91.5, 97.4) compared to 79% in patients treated with R(95% CI: 73.6, 84.1; P<.0001). The EPCORE FL-1 study results were presented during an oral presentation (abstract 466) at the 67th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Florida, featured in the "Emerging Therapies and Immunotherapies in Blood Cancers" ASH press briefing, and have been simultaneously published in The Lancet.